Characterization of cardiovascular risk factors and Framingham score in an HIV-1 population

Sara Moreira Pinto1, Clara Batista2, R. Correia de Abreu2 and Isabel Neves2
1Serviço de Medicina Interna, Departamento de Medicina, ULS Matosinhos, EPE – Hospital Pedro Hispano, Matosinhos, Portugal.
2Serviço de Infectologia, Departamento de Medicina, ULS Matosinhos, EPE – Hospital Pedro Hispano, Matosinhos, Portugal.

*Corresponding author: R. Correia de Abreu, Unidade Local de Saúde de Matosinhos, EPE - Hospital Pedro Hispano, Rua Dr. Eduardo Torres, 4464-513 Senhora da Hora, Matosinhos, Portugal. E-mail: rca.research@outlook.com

Received date: November 03, 2020; Accepted date: November 16, 2020; published date: November 19, 2020

Citation: Sara M. Pinto, Batista C., R. C. de Abreu and Neves L. (2020) Characterization of cardiovascular risk factors and Framingham score in an HIV-1 population. J. Cli Res and Rep. 5(5); DOI:10.31579/2690-1919/0130

Abstract

With the advent of high-potency antiretroviral treatment introduced in 1996, HIV infection ceased to be an acute and deadly disease to become chronic and controllable.

However, the early aging of this population, which according to some authors and cohorts, is 10 years less than in the "normal" population, has been studied.

Although the realities of these patients comorbidities are well known, the definition of time, when and how or with what to treat still seems to be a matter of debate.

The aim of this study is to evaluate the incidence and prevalence according to the state of the art for the non-HIV population of cardiovascular risk factors (hypertension, dyslipidemia, diabetes mellitus) and apply the adjusted Framingham Risk Score by recording analytical and clinical factors in an HIV-1 population with more than 50 years of age, followed in the Infectious Diseases Service for more than 6 months.

Keywords: cardiovascular risk factors; HIV-1 population; Infectious Diseases

Introduction

The introduction of Antiretroviral Therapy (ART) has led to a change in the paradigm of Human Immunodeficiency Virus (HIV) infection/ Acquired Immunodeficiency Syndrome (AIDS). A condition viewed in the past as rapidly progressive and lethal is now seen as a chronic disease, with the different drugs allowing for an increase in survival rates and improvement in the quality of life. As expected, age related diseases are becoming a more frequent topic in HIV clinics [1].

Although mortality rates in an HIV population are 3 to 15 times superior to the general population, more than half are due to non-infectious complications, such as cardiovascular diseases, essential hypertension, diabetes and chronic kidney disease [1, 2]. These comorbidities are the result of a complex interaction between the virus, the host and ART. The virus is responsible for a state of chronic inflammation with endothelial hypercoagulation [2]. Several studies have showed that uncontrolled viral replication is an independent risk factor for lipid changes such as LDL and triglycerides increase, as well as lowering of HDL [3, 4]. Another mechanism that seems to be present, is the homeostasis of the fat tissue, with HIV promoting a state of lipodystrophy with redistribution of fat, with an increase in visceral deposition. There seems to be also an increase in endothelial inflammation with significant impact in the vulnerable atherosclerotic plaques, related to lymphocytes T CD4+ nadir and the number of HIV copies/ mL in the blood [2, 3, and 5].

The host plays an essential role, not only due to genetic factors that increase the cardiovascular risk per se, but also for other comorbidities and therapeutics. Age, male gender and genetics, are non-modifiable features that influence cardiovascular risk. On the other spectrum, modifiable factors like life style, exercise, smoking, alcohol and other drugs also influence the risk of cardiovascular events and precocious death, with HIV population having a higher prevalence of the last factors mentioned [2, 3].

Last but not least, ART therapy has been associated with lipid changes not fully understood yet. Over the years, there have been several studies with controversial results, with the Swiss HIV Cohort showing a rapid increase in total cholesterol, LDL and HDL after the beginning of ART, contrasting with MACS cohort in which the levels decreased after ART [7, 9, and 10].

All the current guidelines recommend cardiovascular disease prevention, starting with the risk assessment and adjusting treatment to each patients individual profile and risk. Despite the several studies, it is still difficult to define the exact risk score values that should motivate an immediate pharmacological intervention [6, 9, and 12]. Therefore, risk categories were defined to help design an individual approach for each patient according to their specific probability of a cardiovascular event [9]. According to the European Society of Cardiology (ESC) and the American College of Cardiology (ACC), physicians should do a systematic risk evaluation of family history of cardiovascular diseases,
smoking, essential hypertension, diabetes and lipid changes. If in healthy individuals this assessment should be made every 5 years after 40 years of age in men and 50 years of age in women, the presence of a condition like HIV should illicit an earlier assessment and intervention if necessary [12].

There are a number of cardiovascular risk scores that assess the probability of an event at 5 years, like the D.A.D. score or a 10year event like Framingham or PROCAM. In the several studies, it seems to be consensual that the D.A.D. score overestimates the 5year risk in HIV patients when compared to Framingham or PROCAM scores. On the opposite side, Framingham underestimates the percentage of low risk HIV patients [6, 9]. Based upon this, Giovanni Guaraldi proposed that Framingham risk score should be adjusted to this specific population, by adding 10 years to the real patient age in order to standardize the results and allow a more rigorous assessment [1, 13]. Patients are considered to be of low risk if they present with an adjusted Framingham score of less than 10%; moderate risk if the percentage stays between 10 and 20 and high risk when above 20%. By defining this, the physician can define an individual strategy towards controlling the risk factors and preventing cardiovascular events.

Methods
We conducted a retrospective transversal observational study, by which we characterized a population with HIV-1, with more than 50 years of age in 2019, followed in the Infectious Diseases Service at Hospital Pedro Hispano for more than 6 months. We evaluated their demography, their cardiovascular risk factors, including age and gender, as well as smoking, essential hypertension, diabetes and lipid changes. We also recorded characteristics of their HIV, such as number of years with the disease, treatment, number of lymphocytes T CD4+ and T CD8+ cells and viral load of the virus at each appointment. We later proceeded to analyse their Framingham score and adjusted Framingham score.

The statistical treatment of the data was conducted through Excel and IBM SPSS®, version 20. The study was conducted according to the recommendations of the Declaration of Helsinki of the World Medical Association.

Results
In table 1 we present the sociodemographic characteristics of our 160 appointments, where 75% were men, with a mean age of 60 years old. Patients were infected with HIV between 2 and 31 years, with a mean number of years of infection of 13 and the main form of transmission being sexual in 87.5% of the cases.

Regarding the infection per se, the mean viral load of patients was 97 [0-14366] copies/µL, with most patients having zero copies (89%, n=143). The mean number of TCD4+ cells was 663 [148-1430] and TCD8+ cells was 887 [271-3356]. A total of 47 patients (29%) were defined to have AIDS.

When looking for deeper characterization of HIV infection, we found that most patients – 50.6% (n=81) were in CDCs stage A1 at the time of the appointment, followed by 15.6% in stage A2 or C1 (n=25) and 13.1% (n=21) in stage C2 – see table 2.

| CDC Stage of HIV infection | n   | %   |
|---------------------------|-----|-----|
| A1                        | 81  | 50.6%|
| A2                        | 25  | 15.6%|
| A3                        | 0   | 0.0% |
| B1                        | 5   | 3.1% |
| B2                        | 2   | 1.3% |
| B3                        | 0   | 0.0% |
| C1                        | 25  | 15.6%|
| C2                        | 21  | 13.1%|
| C3                        | 1   | 0.6% |
| Total                     | 160 | 100.0%|

| ART in this HIV population |
|----------------------------|
| Effective antiretroviral   |
| drugs                      |
| TDF/FTC/ELV/C              |
| TDF/FTC/ETR/P              |
| TAF/FTC/ETR/P              |
| TDF/FTC/EFV                |
| TDF/FTC/RLP                |
| TAF/FTC/ETR/P              |
| Number of patients (%)     |
| 100,0%                     |
| 86.6%                      |
| 60.6%                      |
| 51.0%                      |
| 44.3%                      |
When looking at the events, 9 patients had myocardial infarctions and there were a total of 4 ischemic strokes (3 in one patient alone).

For further characterization, we found that the mean total cholesterol of our population was 179 [101-287] mg/dL, the mean LDL was 108 [42-195] mg/dL the mean HDL was 49 [24-106] mg/dL, and the mean triglycerides was 119 [41-993] mg/dL. Finally, we looked at Framingham risk score and the adjusted score like Guaraldi suggested. We found that most patients, 66% (n=106) had a high risk of 10-year mortality and events in the adjusted Framingham risk score compared to 48% (n=77) in the non-adjusted risk score – Table 4. A total of 10 patients switched from low risk to moderate risk and 29 patients switched from moderate risk to high mortality risk, when changing from the general score to the adjusted one.

| Framingham risk score | Adjusted Framingham risk score |
|-----------------------|-------------------------------|
| Low risk              |                               |
| n        | %    | n        | %    |
| 31       | 19   | 21       | 13   |
| Moderate risk         |                               |
| 52       | 33   | 33       | 21   |
| High risk            |                               |
| 77       | 48   | 106      | 66   |

Table 4. Framingham and adjusted Framingham Risk Score

**Discussion**

We conducted this analysis in order to characterize a specific HIV population with over 50 years of age that will undoubtedly increase over the next years due to better diagnosis, better care and bigger variety of ART available [14]. Most of our patients were male and contracted the disease through risk sexual contacts, which is in accordance to the Portuguese report regarding HIV/AIDS infection in 2019 that shows 14.2 male cases per 10⁵ people versus only 5.1 female cases per 10⁵ people and more than 80% being transmission through sexual contact [15].

Another highlight of our cohort, is the fact that most of our patients are probably very well adherent to ART. One can speculate about this fact since mean viral load didn’t reach 100 [0-14366] copies/mL and mean CD4⁺ was above 500 [148-1430] cells/mL. Alongside, the fact that most of our patients are in the A1 clinical stage which corresponds to having over 500 T CD4⁺ cells/mL and no opportunistic infection.

When looking at AIDS defining conditions, of our 47 patients, the most common one was *Pneumocystis jiroveci* infection, followed by Pulmonary Tuberculosis. According to the 2019 Portuguese report on HIV/AIDS infection, *Pneumocystis jiroveci* was still the most common opportunistic condition representing 34.5% of all AIDS defining diseases in Portugal in 2018 [15]. On the other hand, Pulmonary Tuberculosis was less frequent in the report, represented in 11.9% of people with AIDS, coming only after Oesophageal Candidiasis and Cytomegalovirus infection [15].

As expected, the most frequently used class of ART were INIs and NRTIs. These are first-line therapeutics in naïve patients, with Raltegravir being the most frequently used medication [16].

When looking at the cardiovascular risk factors, dyslipidaemia was the most frequent risk factor in agreement several series in the literature. For example, the HOPS study group reports a prevalence of 81% in HIV positive men and 67% among HIV women [17], while ours reports a prevalence of 86% among total population. The second most prevalent risk factor was essential hypertension, present in almost half the patients included. This is also in accordance to several cohorts, with the same HOPS sample mentioning between 54.4 and 57.4% of the HIV population having essential hypertension [17]. Last but not least, diabetes was present in 16% with the MACS cohort mentioning a similar prevalence of 14% (2, 18).

By analysing the Framingham risk score, we realize that most of our patients had a high risk of myocardial infarction or death at 10 years, meaning a risk above 20%. This was the case in both the Framingham and the adjusted Framingham risk score, with the later one including 29 more patients than the first one. As we know, the accuracy of these risk scores for predicting cardiovascular events in HIV-infected patients is not well established [6]. In the Nery et al cohort, only 5.7% of the patients were classified as having high risk, but with a different, younger, population [6]. On the other hand, by applying the adjusted score, the authors also found an increase in the number of patients classified has having intermediate or high score, as expected [6, 9]. According to Pris et al, Framingham risk score underestimated the cardiovascular event risk in their HIV population, defending that a high proportion of patients classified has having low risk, had already subclinical atherosclerosis [9]. Although a high proportion of our patients had a high risk score, it would be interesting to evaluate if the patients with a low or moderate risk score, already had atherosclerotic changes.

**Conclusion**

Due to notable extension of life expectancy in HIV-infected patients, cardiovascular complications are becoming more frequent as this population ages. This indicates the necessity of routine screening, appropriate monitoring and management of the broad spectrum of risk factors contributing to cardiovascular complications. Although the several risk scores help stratify the risk of these events, these equations were not developed to assess cardiovascular risk in HIV-infected patients, and their accuracy in this population is still uncertain. A different tool, validated and appropriate for an HIV population is needed, instead of an adjustment of the existing ones.

**Conflicts of interest**

Sara Moreira Pinto declares no conflicts of interest.

Clara Batista declares no conflicts of interest.

R. Correia de Abreu declares to have received honorary fees from Gilead Sciences, Janssen, ViiV / GlaxoSmithKline and Merck Sharp & Dohme and research funding from Merck Sharp & Dohme.

Isabel Neves declares to have received honorary fees from Gilead Sciences, Janssen, ViiV/GlaxoSmithKline e Merck Sharp & Dohme and research funding from Merck Sharp & Dohme.

**References**

1. Guaraldi G, Orlando G, Zona S, Menozzi M et al. (2011) premature age-related comorbidities among HIV-infected persons compared with the general population. HIV/AIDS. Oct 13: 119, 1120-1126.

2. Stein J H, Mascolini M. (2013) Pointers on cardiovascular disease risk, screening and management in patients with HIV | Cardiovascular risk factors with HIV heart protector? | When and how to screen for cardiovascular disease risk in people with HIV. Magazine - The center of AIDS information & Advocates. Volume 18, No 1. Summer. ISSN 2163-6842.

3. Fedele F, Bruno N, Mancone M. (2011) cardiovascular risk factors and HIV disease. AIDS. Ver.13:119-29.

4. Grinspoon. (2014) cardiovascular disease in HIV: traditional nontraditional risk factors. IAS-USA: Topics in antiviral medicine. Cardiovascular disease in HIV; Vol 22; issue 4. 676:679.

5. Triant V. (2013) Cardiovascular disease and HIV infection. Curr HIV/AIDS Rep. 10(3):199-206.

6. Nery M, Martelli C T, Silveira E A , Sousa C A et al. (2013) cardiovascular risk assessment: a comparison of the Framingham, PROCAM and DAD equations in HIV-infected persons. The scientific journal. *Online publication*. 969281.
7. Lipshultz S E, Fisher S D, Lai W W, Miller T L. (2003) Cardiovascular risk factors, monitoring and therapy for HIV-infected patients. AIDS 17 (suppl 1):S96-S122.
8. Nsagha D S, Assob J C N, Njunda A L, Tanue E A et al . (2015) Risk factors of cardiovascular disease in HIV/AIDS patients on HAART. The open AIDS journal. 9; 51-59.
9. Piris M, Jug B, Sabovic M, Karner P, Poljak M, Tomazic J. (2014) Cardiovascular risk assessment in HIV-infected male patients: a comparison of Framingham, SCORE, PROCAM and DAD risk equations. Acta Dermatovenerologica APA. 23:43-47.
10. Mashinya F, Alberts M, Van geertruyden J, Colebunders R. (2015) Assessment of cardiovascular risk factors in people with HIV infection treated with ART in rural South Africa: a cross sectional study. AIDS research and therapy. 12:42.
11. Osegbe I, et al. (2016) Risk factors and assessment for cardiovascular disease among HIV-positive patients attending a Nigerian tertiary hospital. Pan African medical journal. 23:206.
12. Peipoli M, Hoes A, Agewall S. et al (2016) The sixth joint task force of the European Society of Cardiology. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal 37; 2315-2381.
13. McComsey G A, Tebas P, Shane E, Yin M et al. (2010) Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 51(8):937-946.
14. Triant VA. (2014) Cardiovascular disease and HIV infection. Curr HIV/AIDS Rep. 10(3):199-206.
15. Direção Geral de Saúde; Instituto Português Ricardo Jorge. Programa Nacional para a infeção VIH/SIDA: Infeção VIH e SIDA em Portugal – 2019. Sistema Nacional de Saúde. Nov 2019
16. European AIDS Clinical Society. Guidelines – version 9.0. October 2017
17. Buchacz K, Baker RK, Palella FJ Jr, et al; (2013) HIV Outpatient Study investigators. Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US. Antivir Ther. 18:65-75.
18. Brown TT, Cole SR, Li X et al. (2005) Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicentre AIDS Cohort Study. Arch Intern Med; 165:1179-84.